2.3.2.5: glutaminyl-peptide cyclotransferase
This is an abbreviated version!
For detailed information about glutaminyl-peptide cyclotransferase, go to the full flat file.
Word Map on EC 2.3.2.5
-
2.3.2.5
-
pyroglutamate
-
alzheimer
-
cyclases
-
pyroglutamyl
-
papaya
-
pyroglutamate-modified
-
pglu-a
-
medicine
-
drug development
-
antivenomics
-
pharmacology
-
n-truncated
-
cd47-sirp
- 2.3.2.5
- pyroglutamate
- alzheimer
- cyclases
-
pyroglutamyl
- papaya
-
pyroglutamate-modified
-
pglu-a
- medicine
- drug development
-
antivenomics
- pharmacology
-
n-truncated
-
cd47-sirp
Reaction
Synonyms
AtQC, cyclotransferase, glutaminyl-transfer ribonucleate, DromeQC, gamma-glutamylamine cyclotransferase, GGACT, glutamine cyclotransferase, glutaminyl cyclase, glutaminyl-peptide cyclotransferase-like protein, glutaminyl-tRNA cyclotransferase, golgi resident enzyme, Golgi resident glutaminyl cyclase, Golgi-resident enzyme, Golgi-resident glutaminyl cyclase, gQC, h-isoQC, h-QC, hQC, isoDromeQC, isoGlutaminyl cyclase, isoQC, PgQC, QC, QCT, Qpct, Qpct1, QPCTL, secretory glutaminyl cyclase, sQC, StQC
ECTree
Advanced search results
Application
Application on EC 2.3.2.5 - glutaminyl-peptide cyclotransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
pharmacology
QCT would be suitable for enzyme therapy in gluten intolerance and appear to have synergistic action with porcine intestinal extracts, potential for enzyme therapy in coeliac disease
drug development
development of hQC enzyme inhibitors, 5,6-dimethoxy-N-(3-(5-methyl-1H-imidazol-1-yl)propyl)-1Hbenzo[d]imidazol-2-amine is a potential drug for treatment of Alzheimer's disease
drug development
development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimers disease
drug development
glutaminyl cyclase is a drug target to diminish pE-Abeta formation
drug development
the enzyme is a potential target for the development of novel anti-Alzheimer disease agents. Phenol-40 (R1-), C5-OH (R2-) and C7-OH (R3-) modified apigenin derivatives are synthesized and evaluated as another class of human QC (hQC) inhibitors
-
inhibition of glutaminyl cyclase offers a new therapeutic option for the treatment of Alzheimers disease and provides implications for other amyloidoses, such as familial Danish dementia
medicine
-
the enzyme is a pharmacological target for Alzheimers disease therapy
medicine
-
the enzyme is a pharmacological target for Alzheimers disease therapy
medicine
hQC isozymes, sQC and gQC, inhibition is considered to be an attractive strategy to prevent the formation of pGlu-Abeta and to reduce neuroinflammation and provides an opportunity for the treatment of Alzheimer disease
medicine
the development of hQC enzyme inhibitors can prevent the self-aggregation of Abeta peptides, resulting in impeding Alzheimer's disease
Abeta38, Abeta40 and angiogenesis mediators Flt1, Tie2, VEGFD, CAM-1 and ICAM-1 are potential pharmacodynamic markers of glutaminyl cyclase (QC) inhibition, because their levels closely correlate with QC activity in Alzheimer's disease patients. The addition of QC activity to core diagnostic cerebrospinal fluid (CSF) biomarkers may be of specific interest in clinical cases with discordant imaging and biochemical biomarker results. Core CSF diagnostic biomarkers (Abeta42, tau and p-tau) are not part of the diagnostic workup
pharmacology
glutaminyl cyclase is a drug target to diminish pE-Abeta formation
pharmacology
the glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a target to interfere with the CD47 pathway and thereby augment antibody therapy of cancer